Stocks Technology SOPH
NASDAQ · TechnologySOPHiA GENETICS SA (SOPH)
SOPHiA GENETICS SA reported revenue of $77.3M in fiscal 2025, up 18.6% from a year earlier. It posted a net loss of $79M. In fiscal 2025 capital spending exceeded operating cash flow by $36.5M. At December 31, 2025 it held $70.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 3, 2026.
Key facts about SOPHiA GENETICS SA
- Net worth
- SOPHiA GENETICS SA has a market value (market cap) of $669.1M at the latest share price, and shareholders' equity of $47.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $77.3M (+18.6% year on year), with a net loss of $79M.
- Cash flow
- In fiscal 2025 operations used $35.9M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on March 3, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What SOPHiA GENETICS SA does
SOPHiA GENETICS SA is registered with the SEC under industry code SIC 7374 (Services-Computer Processing & Data Preparation). Its shares trade on NASDAQ under the ticker SOPH.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $77.3M | -$79M | -$1.17 | -$36.5M |
| 2024 | $65.2M | -$62.5M | -$0.95 | -$44.8M |
| 2023 | $62.4M | -$79M | -$1.22 | -$54.7M |
| 2022 | $47.6M | -$87.4M | -$1.36 | -$74.2M |
| 2021 | $40.5M | -$73.7M | -$1.33 | -$60.6M |
| 2021 | $28.4M | -$39.3M | -$0.93 | -$32.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where SOPH ranks in Technology
Latest SEC filings
What SOPHiA GENETICS SA has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- August 4, 2026
- June 22, 2026
- June 22, 2026
- June 4, 2026
- May 19, 2026
- May 8, 2026
- May 5, 2026
- March 3, 2026Form F-3 filing F-3
- March 3, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 19% to $77.3M versus the prior year; diluted EPS -$1.17 versus -$0.95.
Insider trades
What the people running SOPHiA GENETICS SA did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $278.4K and sold $1.6M worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 6, 2026 | Muken RossChief Executive Officer, Director | Bought | 20,000 | $137.2K |
| November 6, 2026 | Cardoza GeorgeChief Financial Officer | Bought | 20,000 | $141.2K |
| October 13, 2026 | Xu ZhenyuChief Scientific Officer | Soldpre-planned (10b5-1) | 4,000 | $28.7K |
| October 12, 2026 | Camblong JurgiExecutive Chairman, Director | Soldpre-planned (10b5-1) | 8,500 | $61.7K |
| October 12, 2026 | Menu PhilippeChief Medical Officer | Soldpre-planned (10b5-1) | 5,000 | $36.3K |
| October 5, 2026 | Muken RossChief Executive Officer, Director | Soldpre-planned (10b5-1) | 9,838 | $80K |
| October 5, 2026 | Xu ZhenyuChief Scientific Officer | Soldpre-planned (10b5-1) | 7,394 | $60.1K |
| October 5, 2026 | Camblong JurgiExecutive Chairman, Director | Soldpre-planned (10b5-1) | 40,172 | $326.5K |
Who owns SOPH
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Generation Investment Management LLP13G, passive with 2 related filers | 10.22% | November 13, 2024 |
| Akre Capital Management, LLC13G, passive with 2 related filers | 5.6% | June 27, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 72 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Generation Investment Management Llp | 6,789,560 | 0 |
| AIGH Capital Management LLC | 3,954,194 | new |
| Akre Capital Management LLC | 3,719,140 | 0 |
| Royce & Associates LP | 3,381,736 | +1,565,424 |
| Principal Financial Group Inc | 2,364,256 | +955,014 |
| Ameriprise Financial Inc | 2,216,752 | new |
| Banque Pictet & Cie SA | 2,208,280 | 0 |
| AWM Investment Company, Inc. | 1,700,000 | new |
| Soleus Capital Management, L.P. | 1,565,000 | -285,000 |
| Silvercrest Asset Management Group LLC | 1,428,470 | new |
| Alta Wealth Advisors LLC | 1,409,160 | 0 |
| Kennedy Capital Management LLC | 917,977 | -9,823 |
| Archon Capital Management LLC | 691,413 | +250,000 |
| Essex Investment Management Co LLC | 663,428 | -29,381 |
| Ensign Peak Advisors, Inc | 444,654 | -300 |
| Hodges Capital Management Inc. | 409,073 | -26,763 |
| Bank Pictet & Cie (Europe) AG | 255,200 | 0 |
| Legato Capital Management LLC | 223,230 | +6,889 |
| 1492 Capital Management LLC | 222,194 | -3,557 |
| Edmond DE Rothschild Holding S.A. | 200,004 | -3,330 |
Insiders
14 insiders reported holding 7,380,325 shares in total, about $58M at the last price.
| Holder | Shares |
|---|---|
| Camblong JurgiExecutive Chairman, Director | 3,387,150 |
| Muken RossChief Executive Officer, Director | 680,391 |
| Xu ZhenyuChief Scientific Officer | 541,493 |
| Ossipow VincentDirector | 522,860 |
| Van Well DaanChief Legal Officer | 332,716 |
| Cox TroyDirector | 328,743 |
| Cardoza GeorgeChief Financial Officer | 326,726 |
| Hirsch DidierDirector | 240,220 |
| Cossery Jean-MichelDirector | 206,212 |
| Valente ManuelaChief People Officer | 206,210 |
Questions about SOPH
What does SOPHiA GENETICS SA do?
SOPHiA GENETICS SA is a company in the Technology sector, listed on NASDAQ as SOPH. Its shares trade on NASDAQ under the ticker SOPH.
What is SOPHiA GENETICS SA's net worth?
SOPHiA GENETICS SA has a market value (market cap) of $669.1M at the latest share price, and shareholders' equity of $47.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is SOPHiA GENETICS SA profitable?
No. In fiscal 2025 it reported a net loss of $79M on revenue of $77.3M.
How much revenue does SOPHiA GENETICS SA make?
In fiscal 2025 SOPHiA GENETICS SA reported revenue of $77.3M. That is 18.6% more than a year earlier.
When did SOPHiA GENETICS SA last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 3, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the planned insider sale from November 9, 2026.
Similar companies
Compare SOPH with
Follow SOPH
Get an email when SOPHiA GENETICS SA files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values SOPHiA GENETICS SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.